Eupraxia Pharmaceuticals (NASDAQ:EPRX) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS

by · The Cerbat Gem

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01), Zacks reports.

Eupraxia Pharmaceuticals Price Performance

Shares of NASDAQ EPRX opened at $7.55 on Thursday. The stock has a market capitalization of $456.25 million, a PE ratio of -7.19 and a beta of 1.19. The business has a fifty day moving average price of $7.33 and a two-hundred day moving average price of $7.28. Eupraxia Pharmaceuticals has a fifty-two week low of $3.67 and a fifty-two week high of $9.32.

Analyst Ratings Changes

EPRX has been the subject of several research reports. Cantor Fitzgerald lifted their price target on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, January 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Tuesday, April 21st. William Blair initiated coverage on Eupraxia Pharmaceuticals in a report on Monday, March 23rd. They set an “outperform” rating for the company. Wall Street Zen raised Eupraxia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, April 18th. Finally, Zacks Research raised Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Check Out Our Latest Research Report on Eupraxia Pharmaceuticals

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of EPRX. Integrated Wealth Concepts LLC bought a new position in shares of Eupraxia Pharmaceuticals in the 3rd quarter valued at $71,000. Bank of America Corp DE increased its stake in shares of Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after purchasing an additional 10,059 shares during the last quarter. Guardian Wealth Advisors LLC NC bought a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter valued at $76,000. Aptus Capital Advisors LLC bought a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter valued at $76,000. Finally, Geode Capital Management LLC bought a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter valued at $105,000.

Eupraxia Pharmaceuticals Company Profile

(Get Free Report)

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.

Recommended Stories